InsidersTradesSigma
Track the DocMorris AG share price and the full directors' dealings record of the company, a listed equity based in Switzerland. Shares are quoted on the CH market, under the supervision of SIX SER. Operating in the Healthcare & Pharma sector, DocMorris AG has published 84 reports. The latest transaction was disclosed on 29 June 2026 (Purchase). Every trade is free.
84
Insider Decl.
n/a
Thresholds
€6m
69 ops.
Buy Volume
€2m
15 ops.
Sell Volume
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,785 of 28,752 companies
13.1
score / 100
Value6
Quality20
FCF yld-37%
Earn yld-43%
EV/EBITDA·
ROE·
Gross mgn22%
Net mgn-12%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 29 June 2026
Declarations84 total
6,688 shares@ CHF 9.0313.3% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q6T00046
6,688 shares@ CHF 9.02741.3% of flowISIN CH0042615283SIX:T1Q6T00046
●
Anonymous (an executive member of the board of directors / member of senior management)
1,321 shares@ CHF 6.61100.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q5M00027
●
Anonymous (Executive member of the board of directors / member of senior management)
1,321 shares@ CHF 6.6050.4% of flowISIN CH0042615283SIX:T1Q5M00027
26,700 shares@ CHF 7.5051.3% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4M00053
26,700 shares@ CHF 7.49794.2% of flowISIN CH0042615283SIX:T1Q4M00053
28,000 shares@ CHF 6.7948.7% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4K00024
28,000 shares@ CHF 6.78754.0% of flowISIN CH0042615283SIX:T1Q4K00024
160 shares@ CHF 3.96190.0% of flowISIN CH0042615283SIX:T1Q3O000A8
●
Anonymous (Executive member of the board of directors / member of senior management)
2,000 shares@ CHF 4.600.5% of flowISIN CH0042615283SIX:T1Q3J00044
25,000 shares@ CHF 4.262.3% of flowISIN CH0042615283SIX:T1Q3J00010
19,800 shares@ CHF 4.101.7% of flowISIN CH0042615283SIX:T1Q3J00028
●
Anonymous (Executive member of the board of directors / member of senior management)
4,269 shares@ CHF 4.05950.9% of flowISIN CH0042615283SIX:T1Q3J00069
●
Anonymous (Executive member of the board of directors / member of senior management)
1,124 shares@ CHF 5.980.3% of flowISIN CH0042615283SIX:T1PCG00060
●
Anonymous (Executive member of the board of directors / member of senior management)
1,250 shares@ CHF 4.800.3% of flowISIN CH0042615283SIX:T1PBL00047
20,000 shares@ CHF 5.44272.3% of flowISIN CH0042615283SIX:T1PAN00011
●
Anonymous (Executive member of the board of directors / member of senior management)
3,400 shares@ CHF 5.931.0% of flowISIN CH0042615283SIX:T1P9Q00013
●
Anonymous (Executive member of the board of directors / member of senior management)
1,754 shares@ CHF 5.69180.5% of flowISIN CH0042615283SIX:T1P9Q00021
●
Anonymous (Executive member of the board of directors / member of senior management)
2,500 shares@ CHF 5.89350.7% of flowISIN CH0042615283SIX:T1P9P00049
●
Anonymous (Executive member of the board of directors / member of senior management)
1,550 shares@ CHF 6.0850.5% of flowISIN CH0042615283SIX:T1P9G00048
●
Anonymous (Executive member of the board of directors / member of senior management)
1,950 shares@ CHF 6.0850.6% of flowISIN CH0042615283SIX:T1P9B00023
●
Anonymous (Executive member of the board of directors / member of senior management)
5,300 shares@ CHF 6.361.7% of flowISIN CH0042615283SIX:T1P6N00032
7,000 shares@ CHF 6.9431.0% of flowISIN CH0042615283SIX:T1P6A00013
●
Anonymous (Executive member of the board of directors / member of senior management)
2,500 shares@ CHF 7.741.0% of flowISIN CH0042615283SIX:T1P6500021
6,000 shares@ CHF 8.60781.1% of flowISIN CH0042615283SIX:T1P5S00033
25 of 84 declarations
About DocMorris AG
DocMorris AG is a European digital health and online pharmacy group listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland. The company was founded in 1993 and developed from a pharmaceutical distribution background into a digital platform focused on access to medicines, healthcare advice, and related services. Its registered office and business management headquarters are in Frauenfeld, Switzerland, reflecting its status as a Swiss-incorporated company. The group operates several e-commerce pharmacies for medical and pharmaceutical products and also provides professional health care services. Its product and service offering includes prescription medicines, over-the-counter drugs, and consumer health categories such as beauty and personal care. Strategically, DocMorris is positioning itself as a broader digital health ecosystem rather than a traditional online retailer. Its stated vision is to connect patients, doctors, pharmacies, and health insurers on a single platform, thereby expanding the company’s role beyond transactional pharmacy sales into recurring digital health services. From a competitive standpoint, DocMorris is one of the better-known pure-play online pharmacy operators in Europe. It combines a strong consumer brand with a multi-country operating footprint across Germany, the Netherlands, Spain, France, Portugal, and Switzerland. This geographic spread supports diversification, but it also exposes the company to country-specific regulation, reimbursement frameworks, and the pace of digital adoption in pharmacy and healthcare. For equity investors, that means the company’s growth profile depends not only on customer acquisition and retention, but also on regulatory execution and operational scalability. Recent developments point to a clear strategic reset toward profitability and technology-led differentiation. In 2025, DocMorris continued to emphasize qualitative growth and operational efficiency, while in 2026 it announced a partnership with Google to accelerate an AI-powered health platform. Management highlighted four focus areas: an AI health companion, an AI-enhanced online pharmacy, operational efficiency, and cloud/data security. The group also announced the closure of its Ludwigshafen site by the end of June 2026, with logistics to be integrated into its highly automated Heerlen facility. Management reaffirmed its target of reaching EBITDA break-even during 2026 and free cash flow break-even during 2027. Overall, DocMorris remains a growth-oriented healthcare technology and pharmacy platform listed in Switzerland, with improving strategic clarity but execution still central to the investment case.
